clinical topic updates

Second-line Treatment for Advanced/Metastatic HR+ HER2- Breast Cancer

by Joseph A. Sparano, MD, FACP

Resistance to endocrine-based therapy remains a challenge in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER......READ MORE

LATEST IN EXPERT PERSPECTIVES

Browse More Articles